Celerion targets biologics, vaccine studies with Irish expansion

Celerion is looking to amp up its share of the biologics and vaccine development markets, launching a new containment room at its Belfast facility that will allow it to compete for study contracts.

The expansion adds a negative-pressure processing room to the facility's early-stage research capacity, allowing Celerion to process live class 2 and class 3 biological products on site.

That will help the company study biologics and vaccines with primary and secondary containment, Vice President Phil Bach said, putting processing and patients all in one facility.

"The addition of the containment room, coupled with our ability in the Belfast clinic to recruit large numbers of study participants, places Celerion in a strong position to conduct studies requiring biologics and vaccines," Bach said in a statement. "Celerion's facility in Belfast continues to go from strength to strength."

Celerion has been focused on expanding its offerings in Ireland this year, in January adding a bronchoscopy suite to the Belfast facility with its eye on Phase I studies of respiratory treatments. The site is already equipped to handle early stage research and bioequivalence, biosimilars, obesity, ophthalmic and gastro-intestinal studies.

- read the announcement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.